Institutional investors are rotating capital toward clinical-stage biotech companies focused on precision medicine, with the oncology precision medicine market projected to reach $303 billion by 2035. Five companies—Oncolytics Biotech, OS Therapies, Sensei Biotherapeutics, Atossa Therapeutics, and Tango Therapeutics—are advancing promising cancer treatments with strong clinical data and FDA support, positioning themselves for potential M&A activity as major pharma companies seek differentiated assets.

Tango Therapeutics announced that its Compensation Committee granted a new employee 367,500 non-qualified stock options at an exercise price of $11.94 per share and 60,000 restricted stock units (RSUs) under the company's 2023 Inducement Plan. The options vest 25% after one year with monthly vesting thereafter, while RSUs vest in three tranches over three years, contingent on continued employment.

Boxer Capital Management disclosed a $9.5 million purchase of 1.1 million shares of Tango Therapeutics (TNGX), increasing its stake to 21.09% of the fund's assets. The clinical-stage biotech company, which develops targeted cancer therapies through partnerships including one with Gilead Sciences, has seen its stock surge 426.7% over the past year.

Tango Therapeutics announced the appointment of Sung Lee, Executive Vice President and CFO at Cytokinetics, to its Board of Directors. Lee brings over 20 years of finance leadership experience from roles at major biopharmaceutical companies including Vir Biotechnology, MorphoSys, Sangamo Therapeutics, and Gilead Sciences. His appointment is intended to support Tango's advancement of its lead program vopimetostat into registrational studies.

Tango Therapeutics' CEO Barbara Weber will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference, presenting a live webcast about the company's precision medicine cancer research.

Tango Therapeutics reported a steep decline in Q2 2025 revenue and wider net losses, with ongoing clinical trials in targeted oncology therapies and the early termination of its Gilead partnership.

Tango Therapeutics initiated a Phase 1/2 clinical trial combining TNG462 with Revolution Medicines' daraxonrasib or zoldonrasib to treat RAS-mutant MTAP-deleted pancreatic and lung cancers, targeting potential new precision cancer therapies.

Tango Therapeutics, a clinical-stage biotechnology company, announced the dosing of the first patient in a Phase 1/2 trial for its drug candidate TNG456 in patients with MTAP-deleted glioblastomas and other solid tumors.

Tango Therapeutics reported its Q1 2025 financial results, highlighting progress in its PRMT5 inhibitor programs, including the ongoing TNG462 Phase 1/2 trial and plans for a combination trial with Revolution Medicines' RAS(ON) inhibitors. The company also provided updates on its other pipeline programs and extended its cash runway into Q1 2027.

ITM Isotope Technologies Munich SE announced the election of Dr. Barbara Weber, CEO of Tango Therapeutics, to its Supervisory Board. Dr. Weber's extensive industry experience and expertise in oncology drug development will be valuable as ITM advances its radiopharmaceutical pipeline.

Tango Therapeutics (TNGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Analysts' ratings for Tango Therapeutics (NASDAQ:TNGX) over the last quarter vary from bullish to bearish, as provided by 4 analysts. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 0 1 0 0 0 1M Ago 1 1 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Tango Therapeutics, presenting an average target of $14.5, a high estimate of $17.00, and a low estimate of $11.00. A decline of 16.33% from the prior average price target is evident in the current average. Understanding Analyst Ratings: A Comprehensive Breakdown The perception of Tango Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Peter Lawson Barclays Lowers Overweight $13.00 $18.00 Robert Driscoll Wedbush Lowers Outperform $11.00 $18.00 Robert Burns HC Wainwright & Co. Maintains Buy $17.00 - Robert Burns HC Wainwright & Co. Raises Buy $17.00 $16.00 Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Tango ...Full story available on Benzinga.com